A Sensitivity Meta-Analysis of Disease-Specific Death in Localized Cutaneous Squamous Cell Carcinoma

Skin Cancer – Research Article

Dessinioti C. · Platsidaki E. · Stratigos A.J.

Author affiliations

1st Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Skin Cancer – Research Article

Received: February 22, 2022
Accepted: April 03, 2022
Published online: May 12, 2022

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Patients with localized cutaneous squamous cell carcinoma (cSCC) have different risk for disease-specific death (DSD) from patients with metastatic cSCC. Patients and Methods: We conducted a sensitivity meta-analysis to identify the risk factors associated with DSD, in patients with localized cSCC at initial diagnosis (without locoregional or distant metastasis). Results: Nine studies, with 5,205 patients, were included. Median follow-up ranged from 18 to 81 months. The number of deaths due to cSCC ranged from 3 to 40. Patients with immunosuppression were almost 2 times more likely to die from cSCC compared to immunocompetent patients (risk ratio: 1.85, 95% CI: 1.32–2.61). There was a positive but nonsignificant overall association with DSD for depth beyond fat, tumor diameter, presence of perineural invasion, location, and thickness. These results should be interpreted with caution, as there was limited evidence-based data on DSD in localized cSCC, due to the small number of studies reporting DSD, the absence of reporting the margin status, the variability of selected risk factors across studies, and the variability of definition of risk factors. Conclusions: In our meta-analysis, in localized cSCC at initial diagnosis, patients with immunosuppression were at significantly higher risk to die from cSCC. Our findings further highlight the need for a standardized set of risk factors to be included in studies on prognosis of cSCC and for including margin status and DSD among the studied outcomes.

© 2022 S. Karger AG, Basel

References Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. Epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60–82. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–66. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419–28. Zeng S, Fu L, Zhou P, Ling H. Identifying risk factors for the prognosis of head and neck cutaneous squamous cell carcinoma: a systematic review and meta-analysis. PLoS One. 2020;15(9):e0239586. Eisemann N, Jansen L, Castro FA, Chen T, Eberle A, Nennecke A, et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol. 2016;174(4):778–85. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115(9):1561–7. Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 Study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):e000775. Grob JJ, Gonzalez R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916–25. Study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma. Clinical Trials.gov Identifier: NCT03969004. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03969004?term=cemiplimab&cond=cutaneous+squamous+cell+carcinoma&draw=2&rank=3 (accessed October 3, 2021. The addition of pembrolizumab to postoperative radiotherapy in cutaneous squamous cell carcinoma of the head and neck. ClinicalTrials.gov Identifier: NCT03057613. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03057613?term=pembrolizumab&cond=Cutaneous+Squamous+Cell+Carcinoma&draw=2&rank=10 (accessed on October 3, 2021. Egger M, Davey Smith G. Principles of and procedures for systematic reviews. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group; 2001. p. 23–42. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed May 4, 2021. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Brinkman JN, Hajder E, van der Holt B, Den Bakker MA, Hovius SE, Mureau MA. The effect of differentiation grade of cutaneous squamous cell carcinoma on excision margins, local recurrence, metastasis, and patient survival: a Retrospective Follow-Up Study. Ann Plast Surg. 2015;75(3):323–6. Conde-Ferreiros A, Corchete LA, Jaka A, Santos-Briz Á, Fuente MJ, Posada R, et al. Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: a Multicenter, Retrospective Cohort Study. J Am Acad Dermatol. 2020;84(6):1708–12. Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of patients with cutaneous squamous cell carcinoma: results of a Prospective Cohort Study. J Invest Dermatol. 2017;137(11):2309–15. Griffiths RW, Feeley K, Suvarna SK. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg. 2002;55(4):287–92. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American joint committee on cancer, international union against cancer, and brigham and women’s hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327–34. Ruiz ES, Koyfman SA, Kass J, Schmults CD. Surgery and salvage limited-field irradiation for control of cutaneous squamous cell carcinoma with microscopic residual disease. JAMA Dermatol. 2019;155(10):1193–5. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-Year, Single-Institution Cohort Study. JAMA Dermatol. 2013;149(5):541–7. Tam S, Yao C, Amit M, Gajera M, Luo X, Treistman R, et al. Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 2020;146(2):128–35. Tschetter AJ, Campoli MR, Zitelli JA, Brodland DG. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5-Year, Multicenter, Prospective Cohort Study. J Am Acad Dermatol. 2020;82(1):139–48. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. Switzerland: Springer; 2017. Union for International Cancer Control. TNM classification of malignant umours. 8th ed. Oxford: WILEY Blackwell; 2017. Keohane SG, Botting J, Budny PG, et al. British association of dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol. 2021;184(3):401–14. Schmults C, Blitzblau R, Aasi S, Alam M, Andersen JS, Baumann BC, et al. NCCN (National Comprehensive Cancer Network) clinical practice guidelines in oncology). Squamous cell skin cancer. Version 2.2021. 2021 Aug 1. Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf (accessed August 24, 2021. Friedman HI, Cooper PH, Wanebo HJ. Prognostic and therapeutic use of microstaging of cutaneous squamous cell carcinoma of the trunk and extremities. Cancer. 1985;56(5):1099–105. Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010;46(9):1563–72. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4):759–65. Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015;37(12):1808–15. Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984;148(4):542–7. Article / Publication Details

First-Page Preview

Abstract of Skin Cancer – Research Article

Received: February 22, 2022
Accepted: April 03, 2022
Published online: May 12, 2022

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif